SCHEMBL3083201

SCHEMBL3083201

CC1(C)CC=C(c2ncccc2[N+](=O)[O-])CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
PDE10A Q9Y233 1/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 2/20 0.37
PKM P14618 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
PAX8 Q06710 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
RAB9A P51151 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29263097 0.84 LMNA (0.39) LMNAPDE10AALDH1A1CYP1A2CYP2C9
SCHEMBL4258529 0.78 TDP1 (0.44) ALDH1A1GAAKMT2AL3MBTL1MAPT
SCHEMBL3083005 0.76 KDM5B (0.37) LMNAMEN1KMT2AKDM5BMAPT
SCHEMBL29445486 0.75 CYP1A2 (0.46) LMNAPDE10AALDH1A1CYP1A2CYP2C9
SCHEMBL3076778 0.75 CYP1A2 (0.46) LMNAPDE10AALDH1A1CYP1A2CYP2C9
SCHEMBL3093923 0.74 PARP1 (0.39) LMNAALDH1A1SMN1; SMN2KDM5BRAB9A
SCHEMBL13147880 0.74 CTSB (0.41) LMNAPDE10AALDH1A1CYP1A2CYP2C9
SCHEMBL29940575 0.73 PDE10A (0.60) LMNAPDE10AALDH1A1CYP1A2CYP2C9
SCHEMBL6512953 0.73 PDE10A (0.60) LMNAPDE10AALDH1A1CYP1A2CYP2C9
SCHEMBL25203079 0.71 HSD17B10 (0.41) LMNAALDH1A1SMN1; SMN2GAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER LMNA 2742/4885PDE10A 3290/4885ALDH1A1 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.